Table 2.
Prevalence of IgG antibody responses against MSP1p19 and PF13 according to different formulations of ELISA and duplex MBA data
| Villagers | Antibody responses to PF13 | Antibody responses to PfMSP1p19 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age-class | No | OD-ratio* | %resp. | MFI-ratio* | %resp. | %ROC** | OD-ratio | %resp. | MFI-ratio | %resp. | %ROC |
| <5y | 11 | 1.9 | 27% | 2.3 | 18% | 18% | 3.7 | 64% | 3.4 | 36% | 36% |
| 5-9y | 39 | 6.0 | 51% | 8.7 | 59% | 54% | 3.6 | 49% | 3.7 | 33% | 56% |
| 10-14y | 34 | 10.3 | 94% | 12.5 | 71% | 71% | 5.1 | 74% | 5.9 | 59% | 74% |
| 15-29y | 65 | 9.4 | 74% | 11.1 | 68% | 68% | 6.6 | 80% | 6.5 | 57% | 63% |
| ≥30y | 68 | 8.7 | 74% | 8.6 | 72% | 72% | 7.5 | 85% | 6.9 | 69% | 79% |
| all | 217 | 8.3 | 71% | 9.7 | 65% | 65% | 5.9 | 74% | 5.8 | 56% | 67% |
*Mean values of antibody responses measured with ELISA and duplex magpix test.
**Incidence of responders using optimal threshold defined by ROC analysis.